Peter Marks, former top FDA vaccine official, joins Eli Lilly

Six months after his abrupt resignation as CBER director, Marks has been hired to run discovery and infectious disease work at the big Indianapolis drugmaker.

By Jonathan Gardner • Oct. 8, 2025

Vertex’s quest for a breakthrough in Type 1 diabetes

The race is on for an insulin-producing treatment that doesn’t require immune suppressing drugs.

By Kelly Bilodeau • Oct. 8, 2025

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Overcoming past mistakes, generics powerhouse Teva embraces an innovative ‘mindset change’

In the three years since a leadership change, Teva has evolved its R&D approach beyond a long history making copycat medicines.

By Michael Gibney • Oct. 7, 2025

Trump administration could lower drug prices by making other nations pay more

The Trump administration often touts its efforts to lower prices in the U.S. by matching what other countries pay, but there’s more to this policy story.

By Kelly Bilodeau • Oct. 6, 2025

With Emma Walmsley exiting GSK, who will be pharma’s top women CEOs?

The only woman to head up a company in Big Pharma is stepping down from the role at the end of the year.

By Meagan Parrish • Oct. 3, 2025

Takeda, in reversal, abandons cell therapy research

The Japanese pharmaceutical company, which had made cell therapy a priority a few years ago, aims to partner its work while prioritizing investments elsewhere.

By Delilah Alvarado • Oct. 2, 2025

Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?

This week’s launch of subcutaneously administered Keytruda Qlex gives Merck a safety net for the cancer drug’s daunting patent cliff.

By Michael Gibney • Oct. 2, 2025

AstraZeneca’s at-home flu vaccine is a breakthrough that could pave the way for others

FluMist Home could be a test case for at-home vaccines against a backdrop of challenging regulatory shifts.

By Alexandra Pecci • Oct. 1, 2025

Top pharma industry conferences in 2026

Where pharma leaders will converge, discuss and navigate the industry’s shifting landscape in 2026.

By Meagan Parrish • Oct. 1, 2025

Will the first fibromyalgia drug in 15 years deliver a breakthrough in pain?

The new treatment may only offer modest benefits, but could gain traction in a market with few other options.

By Kelly Bilodeau • Sept. 30, 2025

As obesity M&A heats up, pharmas could get ‘blinded by opportunity’

With companies racing to secure GLP-1-related assets, there may be risks for moving too fast.

By Kelly Bilodeau • Sept. 29, 2025

Is pharma’s IRA pricing battle running out of steam?

Despite recent court losses, the legal tides could still turn in the industry’s favor.

By Meagan Parrish • Sept. 26, 2025

Can a multibillion-dollar deal put Pfizer in the obesity big leagues?

After a couple failed attempts on its own, Pfizer is hitting the M&A gas to bring in candidates that could help it become a weight loss heavyweight.

By Michael Gibney • Sept. 25, 2025

Why Xoma, a drug royalty firm, is hunting biotech ‘zombies’

The collapse in value of many biotechs over the past few years has created an opportunity for specialists like Xoma to “do the right thing” for the ecosystem and liquidate them, its executives say.

By Gwendolyn Wu • Sept. 25, 2025

Pharma’s next generation of blockbuster antibodies takes a ‘more is better’ approach

Why multi-specific antibodies are seeing a fresh surge of industry buzz.

By Kelly Bilodeau • Sept. 24, 2025

Lilly’s Alzheimer’s efforts depend on newer, better biomarkers and diagnostics

The pharma giant’s R&D in Alzheimer’s didn’t end with last year’s Kisunla approval, and diagnostics could define where the company goes next.

By Michael Gibney • Sept. 23, 2025

With DTC ads under fire, pharma companies need to pivot

An executive order from HHS doesn’t prohibit direct outreach to consumers, but drugmakers will need to rethink their outreach strategies.

By Kelly Bilodeau • Sept. 22, 2025

3 FDA approval firsts that could be around the corner

Several market-altering decisions are on the agency’s docket for the rest of 2025.

By Meagan Parrish • Sept. 19, 2025

How pharma can play a role in the $1 trillion healthcare reinvention

A report from PwC takes a long-term approach to the shifts in healthcare and finds that efficiency in R&D and adaptable business models will define the drugmaker of the future.

By Michael Gibney • Sept. 18, 2025

AI agents are coming to pharma. Here’s what it means for clinical trials.

The high-tech helpers could autonomously navigate tedious tasks — but have to be carefully implemented.

By Kelly Bilodeau • Sept. 17, 2025

From atop Mt. Fuji, a Takeda team heralds a need for human plasma

The climb aimed to raise money and awareness as Takeda ramps up its plasma-derived therapy presence in Japan.

By Alexandra Pecci • Sept. 16, 2025

Moderna and BioNTech pioneered mRNA vaccines. But who will make a mark in therapeutics?

While mRNA changed the game in vaccines, leveraging the technology to develop treatments has been trickier to navigate.

By Kelly Bilodeau • Sept. 15, 2025

4 years from clinic to approval — Precigen’s ‘unprecedented’ FDA nod and what comes next

The company scored the first-ever approval to treat a potentially deadly infection leveraging its gene therapy platform.

By Meagan Parrish • Sept. 12, 2025

Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology.

Growing research suggests various ways weight loss drugs could have an impact in cancer care.

By Michael Gibney • Sept. 11, 2025

A new class of sleep drugs draws Wall Street’s attention

Clinical trial data presented this weekend show drugs from Takeda, Alkermes and Eisai significantly helped people with narcolepsy, heralding a new era of sleep medicine.

By Jacob Bell • Sept. 10, 2025